Equity Overview
Price & Market Data
Price: $0.30
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $3,223,283
Daily Volume: 0
Performance Metrics
1 Week: -21.85%
1 Month: -13.19%
3 Months: -62.49%
6 Months: -83.29%
1 Year: -90.92%
YTD: -89.41%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.